Shares of Affirmed Therapeutics BV (NASDAQ:AFMD) have received a consensus rating of “Buy” from the seven ratings firms that are presently covering the firm. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $11.00.

Several brokerages recently weighed in on AFMD. Leerink Swann raised shares of Affirmed Therapeutics BV from a “market perform” rating to an “outperform” rating in a research note on Monday, July 18th. Jefferies Group reaffirmed a “hold” rating on shares of Affirmed Therapeutics BV in a research note on Tuesday, August 9th.

Several large investors have recently made changes to their positions in the stock. BlackRock Institutional Trust Company N.A. increased its stake in shares of Affirmed Therapeutics BV by 1.6% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 108,911 shares of the biopharmaceutical company’s stock worth $407,000 after buying an additional 1,713 shares in the last quarter. State Street Corp increased its stake in shares of Affirmed Therapeutics BV by 7.7% in the first quarter. State Street Corp now owns 220,885 shares of the biopharmaceutical company’s stock worth $823,000 after buying an additional 15,714 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Affirmed Therapeutics BV by 6.8% in the first quarter. Geode Capital Management LLC now owns 29,204 shares of the biopharmaceutical company’s stock worth $109,000 after buying an additional 1,856 shares in the last quarter. Wellington Management Group LLP increased its stake in shares of Affirmed Therapeutics BV by 237.2% in the first quarter. Wellington Management Group LLP now owns 3,561,141 shares of the biopharmaceutical company’s stock worth $13,318,000 after buying an additional 2,505,031 shares in the last quarter. Finally, Moore Capital Management LP purchased a new stake in shares of Affirmed Therapeutics BV during the first quarter worth approximately $281,000. 42.86% of the stock is currently owned by institutional investors.

Affirmed Therapeutics BV (NASDAQ:AFMD) traded down 0.40% during trading on Monday, hitting $2.46. 58,850 shares of the stock were exchanged. The stock’s 50 day moving average price is $2.74 and its 200 day moving average price is $3.23. Affirmed Therapeutics BV has a 12 month low of $2.34 and a 12 month high of $8.42. The stock’s market cap is $82.38 million.

Affirmed Therapeutics BV (NASDAQ:AFMD) last released its quarterly earnings results on Wednesday, August 10th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by $0.05. The company earned $2.07 million during the quarter, compared to analysts’ expectations of $2.10 million. Affirmed Therapeutics BV had a negative net margin of 440.97% and a negative return on equity of 49.84%. Affirmed Therapeutics BV’s revenue was down 6.4% on a year-over-year basis. During the same period last year, the firm posted ($0.19) earnings per share. Analysts forecast that Affirmed Therapeutics BV will post ($1.12) EPS for the current fiscal year.

About Affirmed Therapeutics BV

Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company’s product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body’s own immune system to fight tumor cells.

5 Day Chart for NASDAQ:AFMD

Receive News & Stock Ratings for Affirmed Therapeutics BV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affirmed Therapeutics BV and related stocks with our FREE daily email newsletter.